title: Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial.
abstract: OBJECTIVE
  We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH).
  
  
  METHODS
  We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18 years or older with ICH within 24 h of onset. The intervention group (n = 20) received celecoxib (400 mg twice a day) for 14 days. The control group (n = 24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th ± 1 day (cut-off value, 20%).
  
  
  RESULTS
  The time from onset to computed tomography scan slightly differed between groups (177 ± 160 min for control vs. 297 ± 305 min for the celecoxib group; P = 0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P = 0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P = 0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6 ± 91.7% vs. 44.4 ± 64.9%; P = 0.058).
  
  
  CONCLUSIONS
  In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.
authors.affiliation: Department of Neurology, Seoul National University Hospital, Seoul, Korea.
authors.forename: S-H
authors.initials: SH
authors.lastname: Lee
authors.forename: H-K
authors.initials: HK
authors.lastname: Park
authors.forename: W-S
authors.initials: WS
authors.lastname: Ryu
authors.forename: J-S
authors.initials: JS
authors.lastname: Lee
authors.forename: H-J
authors.initials: HJ
authors.lastname: Bae
authors.forename: M-K
authors.initials: MK
authors.lastname: Han
authors.forename: Y-S
authors.initials: YS
authors.lastname: Lee
authors.forename: H-M
authors.initials: HM
authors.lastname: Kwon
authors.forename: C K
authors.initials: CK
authors.lastname: Kim
authors.forename: E-S
authors.initials: ES
authors.lastname: Park
authors.forename: J-W
authors.initials: JW
authors.lastname: Chung
authors.forename: K-H
authors.initials: KH
authors.lastname: Jung
authors.forename: J-K
authors.initials: JK
authors.lastname: Roh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001929:Brain Edema / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000068579:Celecoxib; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D015600:Glasgow Coma Scale; D023261:Glasgow Outcome Scale; D006801:Humans; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D011446:Prospective Studies; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D056910:Republic of Korea; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib
keywords: brain edema; celecoxib; clinical trial; intracerebral hemorrhage